8 September 2025
AOTI, INC. (the "Company" or "Group" or "AOTI")
Notice of Results
AOTI, INC. (AIM: AOTI), a medical technology group focused on the durable healing of wounds and the prevention of amputations, announces that it will be releasing its interim results for the six months ended 30 June 2025 on Monday 22 September 2025.
Analyst Meeting
A meeting for analysts will be held at 09:30 British Summer Time (BST) on Monday 22 September, at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD. The presentation will also be held via webcast. To register to attend in person or virtually, contact [email protected]
A recording of the webcast will be made available on AOTI's website following the conclusion of the meeting at https://aotinc.net/investors/financial-reports-publications-2/
Investor Presentation
A presentation for all existing and potential shareholders will be held via the Investor Meet Company platform at 11:30 BST on Monday 22 September.
Questions can be submitted pre-event via your Investor Meet Company dashboard up until 21 September, 09:00 BST, or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet AOTI, INC. via:
https://www.investormeetcompany.com/aoti-inc/register-investor
Investors who already follow AOTI, INC. on the Investor Meet Company platform will automatically be invited.
ENDS
| AOTI, INC. Dr. Mike Griffiths, Chief Executive Officer Jayesh Pankhania, Chief Financial Officer
|
+44 (0)20 3727 1000 |
| Peel Hunt LLP (Nominated Adviser and Broker) Dr. Christopher Golden, James Steel
|
+44 (0)20 7418 8900 |
| FTI Consulting (Financial PR & IR) Ben Atwell, Simon Conway, Natalie Garland-Collins |
+44 (0)20 3727 1000 |
ABOUT AOTI, INC.
AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and Galway, Ireland, providing innovative solutions to resolve severe and chronic wounds worldwide. Its products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. The Company's patented non-invasive Topical Wound Oxygen (TWO2 ®) therapy has demonstrated in differentiating, robust, double-blinded randomized controlled trials (RCT) and real-world evidence (RWE) studies to more-durably reduce the recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88 per cent reduction in hospitalizations and 71 per cent reduction in amputations over 12 months. TWO2 ® therapy can be administered by the patient at home, improving access to care and enhancing treatment compliance. TWO2 ® therapy has received regulatory clearance from the US (FDA), Europe (CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products Administration, Australia (TGA) and in Saudi Arabia. TWO2 ® therapy has also recently received positive recommendation from the Federal Joint Committee of Gemeinsamer Bundesausschuss (G-BA) in Germany and National Institute for Health and Care Excellence (NICE) in the United Kingdom. Also see www.aotinc.net
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.